ticker
Login
business news
Politics And Regulation
Markets
The Economy
Editor's Pick
trading and investing
Stocks
ETFs
Fixed Income
Earnings
Currencies
Commodities
Options
Taxes
Personal Finance
How To Trade
How To Invest
sectors
Biotech/pharma
Consumer
Energy
Financial
Global Markets
Media
Precious Metals
Real Estate
Technology
Transportation
special features
Wall Of Worry
Random Thoughts
Sports Business
Minyanville Press
Video
Hoofy & Boo
Radio
MV PREMIUM
subscriptions
Launch Buzz And Banter
Buzz And Banter
Elliott Wave Insider
Tchir's Fixed Income Report
Cooper's Market Report
Techstrat Report
Optionsmith
The Stock Playbook
Ad Free Minyanville
Minyanville Book Store
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Gilead Sciences, Inc.
(NQ:
GILD
)
55.93
USD
UNCHANGED
Official Closing Price
/ Updated:
8:10 PM EDT, May 22, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
The Reason It Trades, What's Moving ELN, DELL, GILD and KEY
Today 4:00 EDT
from
Marketwired News Releases
La Agencia Europea del Medicamento aprueba la solicitud de comercialización de sofosbuvir de Gilead para el tratamiento de la hepatitis C
May 22, 2013
from
Business Wire Spanish
Gilead Sciences (GILD) Approaches New Upside Target of $57.45
May 22, 2013
from
Comtex SmarTrend® News Briefs
EMA Approves MAA for Gilead's (GILD) Sofosbuvir
May 21, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8359487 for the full story.
Read More
from
StreetInsider.com News Articles
European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C
May 21, 2013
from
Business Wire News Releases
News Behind Insider Trading: American International Group, First Solar, Gilead Sciences, J.C. Penney, U.S. Bancorp, and Chesapeake Energy
May 21, 2013
from
PR Newswire
Gilead Sciences, Inc. (NASDAQ:GILD) Investor Alert: Investigation over Possible Violations of Securities Laws
May 21, 2013
San Diego, CA -- (SBWIRE) -- 05/21/2013 -- An investigation on behalf of investors of Gilead Sciences, Inc. (NASDAQ:GILD) shares over potential securities laws violations by Gilead Sciences and certain...
Read More
from
SBWire - Latest Press Releases
Start Making Profits Now With AMAT, BMY, GILD and RENN
May 21, 2013
from
Marketwired News Releases
Cramer's Watch List Ahead of Big Cancer Conference
May 20, 2013
The American Society of Clinical Oncology meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
Read More
category
BioMarin Pharmaceutical Inc
,
Biotechnology
,
Merck & Co Inc
, and 13 more.
from
CNBC.com News
Bayer says lung drug shows promise in prolonged trial
May 20, 2013
FRANKFURT, May 20 (Reuters) - Bayer said extended use of its experimental riociguat pill to treat a life-threatening form of high blood pressure in the lungs was shown to be safe and effective in a...
Read More
category
companyNews
from
Reuters: Company News
Profitable Trading Secrets Revealed in GILD, NWSA, RF and MTG
May 18, 2013
from
Marketwired News Releases
Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20
May 17, 2013
from
Business Wire News Releases
UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
May 17, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8350777 for the full story.
Read More
from
StreetInsider.com News Articles
Analyst Moves: NOC, GM, GILD
May 17, 2013
This morning, Credit Suisse increased its price target on shares of Northrop Grumman (NOC) to $78 as additional buybacks will boost the stock. In the report, Credit Suisse also increased its EPS...
Read More
category
Stocks
from
Market News Video
AbbVie (ABBV) Has Plenty More Tricks Up Its Sleeve - Barron's
May 17, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8349940 for the full story.
Read More
from
StreetInsider.com News Articles
Lightning Round: Starbucks, Gilead & More
May 16, 2013
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Read More
category
Lightning Round
,
Starbucks Corp
,
Dominion Resources Inc
, and 10 more.
from
CNBC.com News
Gilead anuncia datos de respuesta del estudio de Fase 2 de idelalisib para leucemia linfática crónica no tratada con anterioridad
May 16, 2013
from
Business Wire Spanish
Strategy Behind Our Success, We Get in Early: GILD, MCP, GM and DF
May 16, 2013
from
Marketwired News Releases
With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What
May 15, 2013
A new class of anti-cancer drugs that allow the immune system to attack cancer cells are generating considerable excitement among patients, doctors, and investors. New results being released ahead of...
Read More
category
NYSE:JNJ
,
NYSE:MRK
,
NASDAQ:PCYC
, and 2 more.
from
Forbes Real Time
Gilead Offers Response Data from Phase 2 Study of Idelalisib
May 15, 2013
Gilead Sciences, Inc. (Nasdaq: GILD ) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta,...
Read More
category
Benzinga
,
News
,
FDA
, and 1 more.
from
Latest Articles from Benzinga.com
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
May 15, 2013
from
Business Wire News Releases
Experimental Gilead drug effective in early-stage leukemia trial
May 15, 2013
May 15 (Reuters) - An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into...
Read More
category
companyNews
from
Reuters: Company News
Medical Stocks Gaining Momentum (GILD, HALO, AFFY, AVEO)
May 15, 2013
New York, NY -- (SBWIRE) -- 05/15/2013 -- Gilead Sciences, Inc. (NASDAQ:GILD) shares rose 0.43% $ 56.49 while trading in range of $ 55.09 – 57.10 with average volume 12.93 million shares. GILD price to...
Read More
from
SBWire - Latest Press Releases
Griffin's Blue Ridge Capital Enters CBS (CBS), Citigroup (C), Netflix (NFLX); Exits Apple (AAPL)
May 15, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8340860 for the full story.
Read More
from
StreetInsider.com News Articles
In the Know, Smart Investing in FCX, GILD, AIG and BMY
May 15, 2013
from
Marketwired News Releases
Jim Cramer's 5 Investing Sweet Spots
May 14, 2013
Jim Cramer often advocates themes in the market. These are big picture ideas that he believes will lift the fortunes of companies and by proxy their stocks. Following are 5 themes that he likes right...
Read More
category
Regeneron Pharmaceuticals Inc
,
EOG Resources Inc
,
ENSCO International Incorporated
, and 14 more.
from
CNBC.com News
NASDAQ Gainers Watch List: Tranzyme, Inc. (NASDAQ:TZYM), ICON Public Limited Company (NASDAQ:ICLR), and Gilead Sciences Inc. (NASDAQ:GILD) Added to Growing Stock Report's NASDAQ Gainers Watch List.
May 14, 2013
New York, NY -- (SBWIRE) -- 05/14/2013 -- Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Tranzyme, Inc. (NASDAQ:TZYM), ICON Public Limited Company (NASDAQ:ICLR), and Gilead...
Read More
from
SBWire - Latest Press Releases
4 Stocks Moves Up in Market Cap Rank (BAC, TSLA, LVS, GILD)
May 14, 2013
New York, NY -- (SBWIRE) -- 05/14/2013 -- Bank of America Corp (NYSE:BAC) shares increased 2.43% to $13.30. Bank of America Corp has agreed to pay $1.6 billion in cash to MBIA Inc and will receive the...
Read More
from
SBWire - Latest Press Releases
Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
May 14, 2013
from
Business Wire News Releases
Gilead Sciences, Inc. (GILD) Call Traders Target New Highs
May 14, 2013
Calls were the options of choice on Gilead Sciences, Inc. (NASDAQ:GILD) yesterday, with roughly 27,000 contracts crossing the tape during the course of the session...( Read More )
Read More
category
GILD
from
SchaeffersResearch.com Daily Market Blog
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Stay Connected
WHAT'S POPULAR IN THE VILLE
1
Random Thoughts: A Signal That Bears Watching
Todd Harrison
2
Random Thoughts: The Chasm Between Stocks and Commodities Continues to Widen
Todd Harrison
3
1929, 1987, and 2013: Three of a Kind?
Jeffrey Cooper
4
Apple: Stock Charts Show It May Be Ready for a Reaction Rally
Jason Haver
5
The 10 Trading Commandments
Todd Harrison
See All Articles
»
Financial Product Guide